Max Planck Institute and Cellomics Announce Collaboration for High Content Screening Development
News Nov 02, 2005
The Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), located in Dresden, Germany, and Cellomics, a unit of Fisher Biosciences, recently announced a joint collaboration in the field of High Content Screening (HCS). The institute serves as a hub for numerous academic-industry collaborations in the field of HCS for drug discovery.
Cellomics provides a unique cell-based platform for its global clients in pharmaceutical, biotechnology, and academic institutions.
"We have always put a great effort in building bridges between academia and the industry," says Dr. Ivan C. Baines, Scientific Coordinator and Director of Services and Facilities at MPI-CBG.
"Working with a leader in a given technology provides unique opportunities to make new discoveries. Cellomics is a leader in high content screening instruments and applications - an area where we are very active having recently established a major assay development and screening facility. We anticipate a highly productive collaboration and are delighted to be working with Cellomics."
According to Daniel J. Calvo, President of Cellomics, the collaboration objectives include a mix of applications and new product development, as well as establishing a key demonstration center for Europe. "Max Planck is a perfect partner for us," stated Calvo.
"They have tremendous experience and capabilities in this area and their strong ties to key academic centers across Europe are a real plus. This collaboration will provide valuable input to help drive the development of our product and applications portfolio for the growing academic market."
As part of the Agreement, MPI-MCBG has purchased the Cellomics' ArrayScan® VTI HCS Reader along with its complete portfolio of BioApplications and HCi™ informatics software.